Burning Rock Biotech Limi... (BNR)
Burning Rock Biotech Statistics
Share Statistics
Burning Rock Biotech has 1.03M shares outstanding. The number of shares has increased by 0.14% in one year.
| Shares Outstanding | 1.03M |
| Shares Change (YoY) | 0.14% |
| Shares Change (QoQ) | 2.94% |
| Owned by Institutions (%) | 0.21% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 98 |
| FTD / Avg. Volume | 0.78% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.11 and the forward PE ratio is null. Burning Rock Biotech's PEG ratio is 0.
| PE Ratio | -0.11 |
| Forward PE | n/a |
| PS Ratio | 0.13 |
| Forward PS | 0 |
| PB Ratio | 0.09 |
| P/FCF Ratio | -0.27 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Burning Rock Biotech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.36 |
| Quick Ratio | 3.09 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $683,759.54 |
| Profits Per Employee | $-831,665.39 |
| Employee Count | 786 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 2.52 |
Taxes
| Income Tax | 2.39M |
| Effective Tax Rate | -0.37% |
Stock Price Statistics
The stock price has increased by -62.32% in the last 52 weeks. The beta is 0.67, so Burning Rock Biotech's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | -62.32% |
| 50-Day Moving Average | 4.59 |
| 200-Day Moving Average | 5.19 |
| Relative Strength Index (RSI) | 26.04 |
| Average Volume (20 Days) | 12,600 |
Income Statement
In the last 12 months, Burning Rock Biotech had revenue of 537.43M and earned -653.69M in profits. Earnings per share was -638.4.
| Revenue | 537.43M |
| Gross Profit | 363.23M |
| Operating Income | -669.32M |
| Net Income | -653.69M |
| EBITDA | -517.9M |
| EBIT | -651.3M |
| Earnings Per Share (EPS) | -638.4 |
Balance Sheet
The company has 615.1M in cash and 12.32M in debt, giving a net cash position of 602.77M.
| Cash & Cash Equivalents | 615.1M |
| Total Debt | 12.32M |
| Net Cash | 602.77M |
| Retained Earnings | -3.85B |
| Total Assets | 984.8M |
| Working Capital | 526.39M |
Cash Flow
In the last 12 months, operating cash flow was -255.78M and capital expenditures -9.38M, giving a free cash flow of -265.17M.
| Operating Cash Flow | -255.78M |
| Capital Expenditures | -9.38M |
| Free Cash Flow | -265.17M |
| FCF Per Share | -25.9 |
Margins
Gross margin is 67.59%, with operating and profit margins of -124.54% and -121.63%.
| Gross Margin | 67.59% |
| Operating Margin | -124.54% |
| Pretax Margin | -121.19% |
| Profit Margin | -121.63% |
| EBITDA Margin | -96.37% |
| EBIT Margin | -124.54% |
| FCF Margin | -49.34% |
Dividends & Yields
BNR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for BNR.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 15, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | May 15, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -6.22 |
| Piotroski F-Score | 4 |